Fludarabine-induced bradycardia in a patient with refractory leukemia
To the Editor: A 22-year-old male diagnosed with acute myelogenous leukemia in November 2005 achieved complete remission after two courses of induction chemotherapy with idarubicin (12 mg/ m 2 intravenously for 3 days) and cytosine arabinoside (200 mg/m 2 in a 24-hour infusion for 7 days). He then received an additional two courses of cytosine arabinoside (3000 mg/m 2 ) in a 3-hour continuous intravenous infusion twice daily for 3 days in April 2006 for intensification. Six months later, the leukemia relapsed and was refractory to re-induction chemotherapy (idarubicin 12 mg/m2 on days 1-3 and cytosine arabinoside 200 mg/m 2 on days 1-7 Figure  1a ). Premedication included dexamethasone, granisetron, and metoclopramide, which were prescribed in previous chemotherapy. Thirty minutes after the fludarabine infusion had been started, he developed sudden-onset general weakness, which lessened 5 minutes later. At that time, persistent bradycardia (48 beats per minute) was noted; vital signs were otherwise normal (blood pressure, 120/70 mm Hg; respiratory rate, 20/min; and body temperature, 36.1ºC). ECG revealed sinus bradycardia but no Cytosine arabinoside is frequently used in the treatment of hematologic malignancies, especially acute myelogenous leukemia. Sporadic cases of pericarditis, pericardial effusion, cardiac tamponade, congestive heart failure, and sinus bradycardia have previously been reported as complications of cy- tosine arabinoside. [1] [2] [3] Fludarabine is a purine antagonist that is commonly used for patients with nonHodgkin lymphoma and chronic lymphocytic leukemia. The most common adverse effects are myelosuppression and immunosuppression. Cardiovascular complications of fludarabine are rare, although several cases of congestive heart failure or left ventricular failure have been reported. [4] [5] There are many possible etiologies for the bradycardia seen in the present patient. For example, sepsis, cardiogenic events, electrolyte imbalance, and drugs such as cytosine arabinoside may all cause bradycardia. An adverse drug reaction is considered to be the probable cause of the bradycardia in this patient because no other etiologies were apparent. Cytosine arabinoside seemed an unlikely cause of bradycardia because the patient had received cytosine arabinoside-containing chemotherapy previously. The bradycardia occurred during fludarabine treatment and subsided significantly after completion of the infusion of this drug. Other probable causes of bradycardia had already been excluded and therefore it is reasonable to speculate about a possible relationship between fludarabine and the sinus bradycardia observed in this patient. Clinicians
